Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298063 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1298064 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961543 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2957502 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297864 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297660 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL5776911 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961541 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL6160001 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2518872 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4559908-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | S2CBio Inc. (KR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-119019388-A | 5-And 6-azaindole compounds for inhibiting Bcr-Abl tyrosine kinase | 英莱汶公司 | 2024-11-26 | — | — | CN | disclosed |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024114663-A9 | CRYSTAL FORM OF TRIAZINYL METHYL CYCLOALKYL CARBOXYLIC ACID DERIVATIVE AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024114663-A1 | CRYSTAL FORM OF TRIAZINYL METHYL CYCLOALKYL CARBOXYLIC ACID DERIVATIVE AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-06-06 | — | — | WO | disclosed |
| EP-4349816-A1 | TRIAZINYLMETHYLCYCLOALKYLCARBOXYLIC ACID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| EP-1424333-A1 | Halothenoyl-cyclopropane-1-carboxylic acid derivatives | Newron Pharmaceuticals S.p.A. (IT) | 2004-06-02 | — | — | EP | disclosed |
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-0991637-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORP (US) | 2002-05-29 | — | — | EP | disclosed |
| US-6159984-A | Farnesyl protein transferase inhibitors | SCHERING CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0991637-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057945-A1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030137-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | CYP3A4 1290/4885CYP1A2 1008/4885CYP2D6 851/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | CYP3A4 757/4885CYP1A2 3800/4885CYP2D6 4123/4885 |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | CYP3A4 829/4885CYP1A2 3169/4885CYP2D6 2809/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.